CV Therapeutics About
CV Therapeutics: CV Therapeutics™ is a biopharmaceutical
company focused on the application of molecular cardiology to the discovery, development
and commercialization of novel, small molecule drugs for the treatment of cardiovascular
diseases. (NASDAQ:CVTX) The company is pioneering a new biomedical discipline,
molecular cardiology, which applies advances in molecular biology and genetics
to identify mechanisms of cardiovascular disease that may lead to new targets
for drug discovery. By using novel, small molecules against these disease targets,
CV Therapeutics is building a pipeline of potential products that are designed
to offer improved efficacy and/or fewer side effects compared with existing agents.
Product
Pipeline Data for CV Therapeutics Ranexa (Chronic
Angina); NIH
Data for Trials CV Therapeutics More
on CV
Therapeutics :
Key
Statistics for CV Therapeutics
Regadenoson (Myocardial Perfusion Imaging);
Tecadenoson
(PSVT Atrial Fibrillation);
Adentri (congestive heart failure--CHF)
Basic
Chart for CV Therapeutics